![Matthias Staehelin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Matthias Staehelin
Direttore/Membro del Consiglio presso JFG Life Sciences Stiftung der Universität Basel
Provenienza dei contatti di primo grado di Matthias Staehelin
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
JFG Life Sciences Stiftung der Universität Basel
![]() JFG Life Sciences Stiftung der Universität Basel Investment Trusts/Mutual FundsMiscellaneous JFG Life Sciences Stiftung der Universität Basel engages in the promotion of innovation transfer in the field of life sciences and related areas. It also supports knowledge and technology transfer at the University of Basel. The company was founded on December 20, 2018 and is headquartered Basel, Switzerland.
4
| Foundation/Endowment | Investment Trusts/Mutual Funds | 4 |
Nuclidium AG
![]() Nuclidium AG Miscellaneous Commercial ServicesCommercial Services Nuclidium AG is a private company located in Switzerland that is revolutionizing precision oncology by developing copper-based radiopharmaceuticals for targeted cancer treatment and diagnosis. The Swiss company's product portfolio utilizes the unique properties of copper to achieve improved safety and efficacy with advantageous economics for hospitals and patients. The company overcomes supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. Nuclidium's diverse and interdisciplinary team is focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients. The company's flexible CutraCeTM platform combines copper radiometals with highly specific cancer-targeting molecules to rapidly develop novel diagnostic and therapeutic programs. Nuclidium's differentiated "diagnostic to therapeutic" approach de-risks their development pathway.
2
| Private Company | Miscellaneous Commercial Services | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Matthias Staehelin tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of St. Gallen | College/University | Masters Business Admin | |
University of Basel | College/University | Graduate Degree | |
Zürcher Kantonalbank (Broker)
![]() Zürcher Kantonalbank (Broker) Investment Banks/BrokersFinance Zürcher Kantonalbank (Broker) (ZKB-Broker) is the brokerage business unit of Zürcher Kantonalbank, a state-owned full-service bank founded in 1870, which is headquartered in Zurich, Switzerland. They conduct all investment activities in-house including financial advisory services, research, trading, and asset management. ZKB-Broker is an active trader in securities, foreign currencies, banknotes, precious metals, commodity contracts and financial derivatives on their own account and on behalf of third-party customers. The bank provides underwriting services in domestic debt and equity markets, sales and trading of listed domestic warrants and structured derivatives, and Swiss Franc foreign exchange trading. The firm offers round-the-clock market-making in credit default swaps from Swiss issuers. Their research covers a broad international investment universe and maintains a successful equity, bonds and sustainability research capability, together with independent investment fund research. | Investment Banks/Brokers | Analyst-Equity | |
BioMedPartners AG
![]() BioMedPartners AG Investment ManagersFinance BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector. | Investment Managers | Private Equity Investor | |
Miracor Medical SA
![]() Miracor Medical SA Electronic Equipment/InstrumentsElectronic Technology Miracor Medical SA engages in the development and manufacture of medical devices. Its product PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System has a driving console and associated catheters to improve outcomes for severe heart attack patients. It seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after a heart attack. The company was founded by Werner Mohl in May, 2008 and is headquartered in Vienna, Austria. | Electronic Equipment/Instruments | Director/Board Member | |
Kizoo Technology Capital GmbH
![]() Kizoo Technology Capital GmbH Investment ManagersFinance Kizoo Technology Capital GmbH (KIZOO) is the venture capital arm of Atevia AG, itself a subsidiary of Cinetic Gesellschaft zur Entwicklung & Vertrieb von Medien. The firm was founded by Michael Greve, Matthias Hornberger, and Frank Schüler in 2006. It is headquartered in Karlsruhe, Germany. | Investment Managers | Private Equity Investor | |
Cell Medica Switzerland AG
![]() Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Jomed AG | Corporate Officer/Principal | ||
APEIRON Biologics AG
![]() APEIRON Biologics AG Pharmaceuticals: MajorHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Polyneuron Pharmaceuticals AG
![]() Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
MiniNaviDent AG
![]() MiniNaviDent AG Medical SpecialtiesHealth Technology MiniNaviDent AG develops dental equipment. It develops miniaturized navigation system, which is directly fitted to the surgical handpiece, and which guides the drill in real-time and in 3D to the correct implant position and angle using a ceramic dual-mode-marker and proprietary algorithms. The company was founded in 2013 by Frank Berlinghoff, Philipp Jürgens, Hans-Florian Zeilhofer and Erik Schkommodau and is headquartered in Basel, Switzerland. | Medical Specialties | Director/Board Member | |
BC Platforms AG
![]() BC Platforms AG Data Processing ServicesTechnology Services BC Platforms AG provides powerful genomic data management and analysis solutions. It offers pharmaceutical, biobank, healthcare and academia products. The company was founded by Timo Kanninen in 1997 and is headquartered in Basel, Switzerland. | Data Processing Services | Director/Board Member | |
Revel Pharmaceuticals, Inc.
![]() Revel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Revel Pharmaceuticals, Inc. engages in the provision of therapeutic designer enzymes to degrade molecular damage that accumulates with aging. The company was founded by Aaron Cravens, David Spiegel and Jason Crawford in 2019 and is headquartered in San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
LIfT BioSciences Ltd.
![]() LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | Miscellaneous Commercial Services | Director/Board Member | |
Swiss Nuclides AG
![]() Swiss Nuclides AG Hospital/Nursing ManagementHealth Services Swiss Nuclides AG provides diagnostics and radiopharmaceutical therapy treatment services for cancer patients. The company is based in Aarau, Switzerland. The Swiss company was founded by Leila Jaafar-Thiel and Gustav von Schulthess, and Leila Jaafar-Thiel has been the CEO since incorporation. | Hospital/Nursing Management | Chief Executive Officer | |
Vaximm AG
![]() Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member |
Statistiche
Distribuzione geografica
Svizzera | 14 |
Belgio | 2 |
Germania | 2 |
Austria | 2 |
Stati Uniti | 2 |
Settori
Health Technology | 7 |
Finance | 4 |
Commercial Services | 4 |
Consumer Services | 3 |
Electronic Technology | 2 |
Posizioni
Director/Board Member | 11 |
Corporate Officer/Principal | 4 |
Chief Executive Officer | 4 |
Founder | 3 |
Private Equity Investor | 2 |
Contatti più connessi
- Borsa valori
- Insiders
- Matthias Staehelin
- Connessioni Società